Inhalation and Nasal Spray Generic Drugs Market Insights on Emerging Scope Prophesy
The global Inhalation and Nasal Spray Generic Drugs Market is projected to have a moderate-paced CAGR of 8.96% during the forecast period. The current valuation of the inhalation and nasal spray generic drugs market is US$ 20.78 Bn in 2023. The value of the inhalation and nasal spray generic drugs market is anticipated to reach a high of US$ 49.01 by the year 2033.
The primary factor that
is driving the sales of inhalation and nasal spray generic drugs is the
increasing prevalence of chronic respiratory disorders across the world.
According to the Global Asthma Report, there are around 330 million people
around the world who suffer from asthma, and it is anticipated that this number
is expected to rise to more than 400 million instances by the year 2025. The
primary factors contributing to an increase in the number of people diagnosed
with asthma around the world include increased air pollution, smoking, and
tobacco usage.
The inhalation and
nasal spray generic drugs market are likely to be driven by factors such as the
growing population of elderly people and the increased vulnerability of elderly
people to persistent respiratory disorders. According to projections made by
the WHO, by the year 2030, one in every six persons throughout the globe is
anticipated to be 60 years old or older. In addition to this, it is anticipated
that the global population of such people is expected to reach 2.1 billion by
the year 2050. In addition, the Asthma and Allergy Foundation of America
estimates that around 7.8% of the population in the United States were 65 or
older and had asthma in the year 2020.
However, the demand for
inhalation and nasal spray generic drugs is anticipated to be hampered by
regulatory impediments brought on by strict rules for the selling of generic
medications in countries such as Mexico and Russia. For example, the regulatory
authority of Mexico, COFEPRIS, has announced new rules for the issuance of
registrations of generic pharmaceuticals. These new standards are likely to not
include patents of new therapeutic uses in its linkage system. In addition, COFEPRIS
provides a unique procedure window for the approval of generic pharmaceutical
products in Mexico.
Competitive
Landscape
The following companies
are leaders in the global market for generic inhalers and nasal sprays:
- Mylan N.V.
- Akorn, Operating Company LLC
- Cipla Inc.
- Sandoz International GmBH (Novartis AG)
- Apotex Inc.
- Hikma Pharmaceuticals PLC
- Sun Pharmaceuticals Industries Ltd.
- Beximco Pharmaceuticals Ltd
Read
More@ https://www.futuremarketinsights.com/reports/inhalation-and-nasal-spray-generic-drugs-market
Key
Segments in the Inhalation and Nasal Spray Generic Drugs Market
Drug
Class:
- Bronchodilators
- Combination
Drugs
- Corticosteroids
- Decongestant
Sprays
- Antihistamines
- Others
Indication:
- Asthma
- Chronic
Obstructive Pulmonary Disease (COPD)
- Allergic
Rhinitis
- Others
Patient
Demographics:
- Geriatric
Patient
- Adult
Patient
- Paediatric
Patient
End-user:
- Hospitals
- Homecare
- Others
Distribution
Channel:
- Hospitals
Pharmacy
- Retail
Pharmacy
- Online
Pharmacies
Comments
Post a Comment